CareDx (CDNA) to Announce Earnings on Thursday

CareDx (NASDAQ:CDNA) will likely be announcing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $0.22 per share and revenue of $113.83 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.11 by $0.23. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.The company had revenue of $117.70 million for the quarter, compared to the consensus estimate of $102.03 million. During the same quarter last year, the company posted $0.09 earnings per share. The company’s revenue for the quarter was up 39.3% compared to the same quarter last year. On average, analysts expect CareDx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Stock Down 1.7%

NASDAQ:CDNA opened at $35.75 on Wednesday. The company’s 50 day moving average is $27.53 and its 200-day moving average is $22.18. CareDx has a 12 month low of $11.26 and a 12 month high of $40.47. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -223.44 and a beta of 2.43.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Weiss Ratings lowered shares of CareDx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, July 15th. Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 3rd. Craig Hallum reaffirmed a “hold” rating and issued a $35.00 price target on shares of CareDx in a research report on Thursday, July 16th. BTIG Research boosted their price objective on CareDx from $28.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Finally, William Blair upgraded CareDx to a “hold” rating in a research note on Thursday, July 16th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $33.67.

Insider Activity

In other news, CEO John Walter Hanna, Jr. sold 39,900 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $29.24, for a total transaction of $1,166,676.00. Following the transaction, the chief executive officer owned 661,959 shares in the company, valued at approximately $19,355,681.16. The trade was a 5.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 12,103 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $23.11, for a total transaction of $279,700.33. Following the transaction, the director directly owned 36,686 shares of the company’s stock, valued at $847,813.46. This represents a 24.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 78,936 shares of company stock worth $2,093,708. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On CareDx

Large investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in shares of CareDx during the 4th quarter worth approximately $25,000. Meeder Asset Management Inc. acquired a new position in shares of CareDx in the fourth quarter valued at $79,000. Quantbot Technologies LP acquired a new position in shares of CareDx in the third quarter valued at $89,000. Tower Research Capital LLC TRC lifted its position in CareDx by 120.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock worth $149,000 after purchasing an additional 4,160 shares during the period. Finally, State of Wyoming acquired a new stake in CareDx during the fourth quarter worth $155,000.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.